{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Complete cytogenetic remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Partial cytogenetic remission"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Cytotoxicity is the ability to destroy cells. This will be measured by taking bone marrow samples and measuring the damage to cells. The level of cell destruction will be correlated with clinical response criteria.","groups":[{"description":"INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \\< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.\n\nflow cytometry: Correlative studies\n\nDNA methylation analysis: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ndecitabine: Given subcutaneously\n\nmicroarray analysis: Correlative studies\n\ngene expression analysis: Correlative studies\n\npharmacological study: Correlative studies\n\npolymorphism analysis: Correlative studies","id":"OG000","title":"Arm I: Decitabine 0.2mg/kg"}],"paramType":"NUMBER","populationDescription":"Patients with chromosomal abnormalities which were evaluable for follow-up karyotyping","reportingStatus":"POSTED","timeFrame":"6 weeks after treatment","title":"Proportion of Patients With Bone Marrow Evidence of Cytotoxicity.","type":"SECONDARY","unitOfMeasure":"participants"}